This study focuses on people with Type 2 asthma characterized by an eosinophilic phenotype, which is a form of asthma associated with increased levels of specific inflammatory cells called eosinophils in the blood. The study will test a medication called depemokimab, which is given as an injection under the skin (subcutaneous injection).

The purpose of this research is to understand how depemokimab affects the structure and function of airways in people with this type of asthma. The study will specifically look at changes in the amount of mucus in the lungs and the thickness of airway walls. The treatment period will last 52 weeks, with participants receiving regular doses of the study medication.

During the study, participants will undergo various tests including high-resolution CT scans of their lungs. Some participants may also take part in an optional procedure called a bronchoscopy, which involves inserting a thin tube with a camera into the airways to collect small tissue samples. The study will measure how the airways change over time while participants are receiving the study medication.